24 May
2024
22:30 E.S.T.

Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

Read more

06 May
2024
02:05 E.S.T.

Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

Read more

02 May
2024
14:49 E.S.T.

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

Read more

29 Apr
2024
15:05 E.S.T.

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

Read more

22 Apr
2024
11:16 E.S.T.

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Read more

10 Apr
2024
10:26 E.S.T.

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

Read more

08 Apr
2024
05:37 E.S.T.

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

Read more

16 Jan
2024
16:30 E.S.T.

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

Read more

22 Dec
2023
16:30 E.S.T.

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

Read more

17 Nov
2023
16:30 E.S.T.

Cellectis’ Shareholders Meeting to be Held on December 22, 2023

Read more